Biosafety
Advarra Announces Key Growth Milestone for The Gene Therapy Ready Network, Becoming Largest IBC Service
Advarra's network has grown to over 500 registered research sites, becomes the largest administrator of institutional biosafety committees
Cell & Gene Therapy vs Drug Research: What’s the Difference?
In the past year, cell and gene therapy research has exploded. Understand how this field differs from traditional drug development.
IBC Overview eLearning Module
Institutional biosafety committee oversight is necessary to ensure the safety of those involved in research with engineered genetic materials.
Daniel Eisenman, Paul Gulig, and Adam Soloff Explore The Exponential Rise of Gene Therapy and Unlocking Its Potential Promise
In this podcast, Daniel Eisenmann talks with Adam Soloff and Paul Gulig for a discussion on the growth and the promise of gene therapy.
Pitfalls of Chemistry, Manufacturing, and Controls in Investigational New Drug Preparation
Submitting an Investigational New Drug (IND) application for the first time? Consider three common CMC pitfalls that may impact submission.
World’s Largest CRO Leverages Partnership With Integrated Central IBC to Initiate Sites in COVID-19 Vaccine Research at Warp Speed
Advarra’s IRB and IBC reviews and Gene Therapy Ready site network helped reduce study startup timelines and delivered trial results to the sponsor quicker than expected.
What Is an Institutional Biosafety Committee?
An institutional biosafety committee (IBC) ensures research is conducted safely and in compliance with the NIH guidelines. Watch our video to learn the role of an IBC.
Study Startup Success for BioPharma and MedTech: Engage a Research Compliance Partner
Engaging with an expert research compliance partner throughout the clinical development process allows researchers to focus on what matters
Meridian Builds Robust Gene Therapy Research Program
Partnering with Advarra’s Institutional Biosafety Committee, Meridian Clinical Research established a program for conducting clinical trials with cutting edge, genetically engineered vaccines.
How Sites Can Win in the New Age of Genetically Engineered Treatments
The accelerating gene therapy market is expected to grow 16.6 percent by 2027. As gene therapies enter the pipeline, how can sites prepare themselves to take advantage of the rush?
Biosafety, Ethical, and Logistical Challenges to Pursuing a Coronavirus Vaccine at Warp Speed
The SARS-CoV-2 pandemic has impacted all aspects of society. Various government and private groups around the world are endeavoring to develop safe and effective vaccines at an unprecedented pace and scale to quell the pandemic as quickly as possible.
Subscribe to our monthly email
Receive updates monthly about webinars for CEUs, white papers, podcasts, and more.
Advancing Clinical Research: Safer, Smarter, Faster™
Copyright © 2024 Advarra. All Rights Reserved.